|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date19 Aug 2014 |
比较每日两次和一次口服Genz-112638治疗对已接受每日两次治疗达到临床稳定的I型戈谢病患者影响的III期临床研究
[Translation] Phase III study comparing twice-daily versus once-daily oral Genz-112638 in patients with type 1 Gaucher disease who have achieved clinical stability on twice-daily therapy
在使用Genz-112638每日两次口服治疗达到临床稳定的I型戈谢病患者中,比较每日一次给药相对于每日两次给药的疗效和安全性,评价药物游离碱基Genz-99067的药代动力学。
[Translation] To evaluate the pharmacokinetics of the free base Genz-99067 in patients with type I Gaucher disease who were clinically stable on twice-daily oral Genz-112638 compared with once-daily dosing and safety.
100 Clinical Results associated with Genzyme (Shanghai) Biopharmaceutical Service Co., Ltd.
0 Patents (Medical) associated with Genzyme (Shanghai) Biopharmaceutical Service Co., Ltd.
100 Deals associated with Genzyme (Shanghai) Biopharmaceutical Service Co., Ltd.
100 Translational Medicine associated with Genzyme (Shanghai) Biopharmaceutical Service Co., Ltd.